Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.

Abstract: Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin expression inhibitor binding compounds, culture media having reduced concentrations of toxin inhibitor metabolic precursors and genetically modified toxogenic bacteria lacking enzymes required to metabolize the toxin inhibitor metabolic precursors.

Abstract: Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin expression inhibitor binding compounds, culture media having reduced concentrations of toxin inhibitor metabolic precursors and genetically modified toxogenic bacteria lacking enzymes required to metabolize the toxin inhibitor metabolic precursors.

Abstract: This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently linked to protein or liposomes to form immunogenic conjugates. The method of immunization for this invention comprises administering to an individual an immunogenic amount of group A polysaccharide. The group A polysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, the group A polysaccharides may be associated with an adjuvant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at risk of contracting group A Streptococcal infections and disease namely adults, pregnant women and in particular infants and children.

Abstract: Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin expression inhibitor binding compounds, culture media having reduced concentrations of toxin inhibitor metabolic precursors and genetically modified toxogenic bacteria lacking enzymes required to metabolize the toxin inhibitor metabolic precursors.

Abstract: The present invention provides antigenic compositions and methods for treatment and prevention of infection and disease caused by group A and group C streptococci. In particular, the invention provides low molecular weight hyaluronic acid, low molecular weight hyaluronic acid linked to a carrier and compositions comprising them. The compositions elicit antibodies to low molecular weight hyaluronic acid which are cross-reactive with group A and C streptococci and which are minimally cross-reactive with native hyaluronic acid. The invention is particularly useful for providing both active and passive immunogenic protection for those infected with or at risk of infection with group A and group C streptococci. Additionally, the present invention provides methods and compositions useful for diagnosing infections and diseases caused by group A and group C streptococci.

Abstract: A procedure to isolate large quantities of capsular polysaccharides (CPS) from culture supernatants as well as bacterial cells of gram-negative and gram-positive bacteria using base extraction is described. The procedure is simple, rapid, reproducible and applicable to a variety of bacterial species. The method also yields novel CPS characterized by their lack of covalent attachment to extraneous peptidoglycan. Vaccines and methods of immunization against bacterial infection using the CPS obtained by the process of the invention are also disclosed.

Abstract: A procedure to isolate large quantities of capsular poly saccharides (CPS) from culture supernatants as well as bacterial cells of gram-negative and gram-positive bacteria using base extraction is described. The procedure is simple, rapid, reproducible and applicable to a variety of bacterial species. The method also yields novel CPS characterized by their lack of covalent attachment to extraneous peptidoglycan. Vaccines and methods of immunization against bacterial infection using the CPS obtained by the process of the invention are also disclosed.

Abstract: Disclosed and claimed is a novel inexpensive and efficient method for the early detection of HIV infection in babies. The method utilizes a unique IgA capture ELISA procedure for detection of HIV-specific antibodies.

Abstract: The subject invention concerns the production and novel use of human anti-HIV IgA antibodies to confer passive immunity to HIV when administered in vivo to a subject. The IgA antibodies of the subject invention are selectively transported to and secreted in the mucosal tissue of the subject. The IgA antibodies can confer protection from HIV infection at locations within the body where HIV penetration usually occurs.

Abstract: The subject invention pertains to methods of treating immunocompromised patients, such as individuals infected with HIV, that exhibit elevated levels of IgA relative to IgG. The use of IgA-binding compositions immobilized onto a support matrix to extracorporeally remove IgA molecules from a sample or biological fluid for therapeutic purposes is provided by the present invention. The subject invention further pertains to novel polypeptides which bind in a specific manner to human IgA. The polypeptides of the present invention comprise an IgA-binding region from an IgA-binding protein of Group B streptococcal bacteria.

Abstract: Describes IgA binding protein isolatable from Group B streptococci, methods of isolation and use in immunological testing procedures.

Abstract: Describes IgA binding protein isolatable from Group B streptococci, methods of isolation and use in immunological testing procedures.